Metformin for pancreatic cancer
Mené aux Pays-Bas sur 121 patients atteints d'un cancer du pancréas de stade avancé, cet essai multicentrique randomisé de phase II évalue l'efficacité, du point de vue de la survie globale à 6 mois, et la toxicité de l'ajout de metformine à un traitement combinant gemcitabine et erlotinib
Metformin is the most widely used oral anti-diabetic drug worldwide. It inhibits hepatic gluconeogenesis and increases insulin sensitivity in peripheral tissues, leading to reduced blood glucose and insulin concentrations. The observation from retrospective studies that metformin might decrease the risk of cancer and mortality in patients with diabetes has prompted the initiation of numerous preclinical and clinical studies to investigate its anticancer activity.
The Lancet Oncology , commentaire, 2014